Psychedelics is one of the fastest-growing areas of the cannabis-related industry and is now one of the 12 subsectors covered by the Viridian Capital Deal Tracker, Value Tracker, and Credit Tracker.
-
Investors perceive a rapidly growing market for psychedelic drugs fostered by the global need for effective mental health treatments, evolving legislation, and supportive public opinion. A recent study by Fairfield Market Research projects demand increasing to $6.3B by 2026, a 16% CAGR. In clinical trials, Psilocybin has been found to be as effective as the leading anti-depression medications with fewer adverse side effects and lower relapse rates. Research is underway on synthetic forms of Ketamine and other psychedelics as well.
